<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949634</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC -DMS- BC-08</org_study_id>
    <nct_id>NCT03949634</nct_id>
  </id_info>
  <brief_title>Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)</brief_title>
  <official_title>Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD）：an Dynamic Randomized, Positive Control, Open, Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, open, controlled Post-Marketing Study. 272 early stage
      female breast cancer patients who were histopathology confirmed with adjuvant chemotherapy
      indications were enrolled in this study .The subjects will be randomly assigned to one of the
      two treatment groups at a 1: 1 ratio, and stratified by trastuzumab,age,baseline cardiac risk
      factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive one of two treatment regimens:

      Group A: intravenous infusion of pegylated liposomal doxorubicin（PLD） 35 mg/m2, d1;
      cyclophosphamide 600 mg/m2, intravenous infusion, d1; once every 21days, for 4 cycles.
      Sequential docetaxel 100 mg/m2, intravenous infusion, d1, or paclitaxel 80mg/m2,intravenous
      infusion, d1,8,15, once every 21 days, for 4 cycles.

      Group B: intravenous infusion of doxorubicin 60 mg/m2, d1; cyclophosphamide 600 mg/m2,
      intravenous infusion, d1; sequential docetaxel 100 mg/m2, intravenous infusion, d1, or
      paclitaxel 80mg/m2,intravenous infusion, d1,8,15, once every 21days, for 4 cycles. The
      primary endpoint is cardiotoxity,the secondary endpoint is 5-year disease-free survival
      (DFS), 5-year overall survival (OS), and safety: hematology and non hematological toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiotoxity</measure>
    <time_frame>2 years.</time_frame>
    <description>Congestive heart failure with clinical symptoms, or no symptoms but an abnormal LVEF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year DFS</measure>
    <time_frame>5 years</time_frame>
    <description>5-year disease-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year OS</measure>
    <time_frame>5 years</time_frame>
    <description>5-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence and Severity of adverse events according to the CTC AE V4.03</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PLD plus CTX sequential docetaxel or PTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOX plus CTX sequential docetaxel or PTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.</description>
    <arm_group_label>PLD plus CTX sequential docetaxel or PTX</arm_group_label>
    <other_name>duomeisu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX</intervention_name>
    <description>cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.</description>
    <arm_group_label>DOX plus CTX sequential docetaxel or PTX</arm_group_label>
    <arm_group_label>PLD plus CTX sequential docetaxel or PTX</arm_group_label>
    <other_name>huanlinxianan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.</description>
    <arm_group_label>DOX plus CTX sequential docetaxel or PTX</arm_group_label>
    <arm_group_label>PLD plus CTX sequential docetaxel or PTX</arm_group_label>
    <other_name>taisudi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.</description>
    <arm_group_label>DOX plus CTX sequential docetaxel or PTX</arm_group_label>
    <arm_group_label>PLD plus CTX sequential docetaxel or PTX</arm_group_label>
    <other_name>taisu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.</description>
    <arm_group_label>DOX plus CTX sequential docetaxel or PTX</arm_group_label>
    <other_name>ameisu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Subjects had histopathologically confirmed early stage breast cancer with adjuvant
             chemotherapy treatment evidence;

          -  2.Age :18-75years old female;

          -  3.High risk of recurrence: axillary lymph node-positive, or axillary lymph node
             negative with at least one of the following risk factors: triple negative breast
             cancer, histological grade III, the maximum tumor diameter&gt; 5cm, Ki 67 ≥ 50%, vascular
             thrombosis positive;

          -  4.ECOG score 0-1;

          -  5.Expected survival time ≥ 12 months;

          -  6.LVEF ≥ 55%;

          -  7.Normal ECG, ST segment depression in patients such as coronary angiography, confirm
             &lt;50% stenosis or incidental premature beats are acceptable;

          -  8.Bone Marrow Function: ANC：≥1.5×109/L； PLT：≥100×109/L；Hb: ≥90g/L;

          -  9.Liver and renal function:Serum creatinine ≤ normal upper limit (ULN) 1.5times;
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ULN 2.5times;
             total bilirubin (TBil) level:≤ ULN 1.5 times, or ≤ ULN 2.5times if Gilbert's syndrome
             are present;

          -  10.Subjects are well-behaved, able to undergo treatment and follow-up, and voluntarily
             comply with this study and understood the study's research process and signed the
             informed consent.

        Exclusion Criteria:

          -  1.New York Heart Association (NYHA) Class II or greater heart failure;

          -  2.Severe heart disease or discomfort, including but not limited to: High-risk
             uncontrolled arrhythmias, atrial tachycardia (heart rate&gt;100/min at rest), significant
             ventricular arrhythmias (ventricular arrhythmias) or higher, atrioventricular block
             ([Mobitz 2] or third-degree atrioventricular block); Angina pectoris that needs to be
             treated with anti-anginal medicine; Valvular heart disease with clinical significance;
             Electrocardiogram shows transmural myocardial infarction; Uncontrolled high blood
             pressure(eg: Systolic blood pressure&gt; 180 mmHg or diastolic blood pressure&gt; 100 mmHg);

          -  3.Prior received neoadjuvant chemotherapy;

          -  4.Severe systemic infection or other serious disease;

          -  5.Allergies to chemotherapeutic drugs or their excipients or intolerant patients;

          -  6.Other malignant tumors have been found in the past 5 years,except for cured cervical
             carcinoma in situ, non melanoma of the skin;

          -  7.Childbearing age patients who are pregnant or lactation and refusing to take
             effective contraceptive measures during the trial;

          -  8.Received any other test drug treatment or participated in other clinical trials at
             the same time;

          -  9.Other conditions considered to be inappropriate to be enrolled by the investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhimin shao, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University affiliated cancer hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jiandong nie, doctor</last_name>
    <phone>0311-66575708</phone>
    <email>niejd@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University affiliated cancer hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lichen tang, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

